ABSTRACT
OBJECTIVE To observe the efficacy of specific immunotherapy (SIT) with Alutard and NHD in children with allergic rhinitis due to different level of skin prick test (SPT) with dermatophagoides farinae (DF) and dermatophagoides pteronyssinus (DP). METHODS A total of 178 children with persistent allergic rhinitis were included in this study. Their age ranged from 6 to 12 years. They were divided into 3 groups according to level of SPT. Group 1: The level of skin index (SI) of DF is greater than that of DP, Group 2: The level of SI of DF is equal to that of DP and Group 3: The level of SI of DF is less than that of DP. The children in each group were randomly divided into 2 subgroups: Alutard group and NHD group. The children were given SIT with Alutard or NHD for one year. Symptom and medication scores were recorded and analyzed. RESULTS After receiving therapy for 3 months and 6 months, symptom and medication scores of the Group 1 and 2 in the NHD group were lower than those in the Alutard group (P0.05). CONCLUSION The efficacy of SIT with Alutard and NHD is different in children with allergic rhinitis with different levels of SPT due to DF and DP after 3 and 6 months, but is similar after 9 and 12 months. SIT with Alutard and NHD is effective in treating children with allergic rhinitis.
ABSTRACT
OBJECTIVE@#To study the mechanism and clinical significance of specific immunotherapy (SIT) on the expression changes of GM-CSF and IL-5 in the tissue samples of recurrent nasal polyps.@*METHOD@#Perennial allergic rhinitis patients with recurrent nasal polyps were randomly divided into 2 groups. The experimental group of 19 patients was treated by SIT and standardized treatment (glucocorticoid nasal spray) , and the control group of 17 patients was only treated by standardized treatment (glucocorticoid nasal spray). We measured the expression levels of GM-CSF and IL-5 in the tissue samples of the nasal polyps by ELISA, and compared the results obtained before treatment with expression levels detected at 6 months and 1 year after the treatment.@*RESULT@#The expression of GM-CSF and IL-5 in the recurrent nasal polyps reduced significantly (P < 0.05) in both groups after 6 months and 1 year post-treatment compared with pre-treatment, and the expression of GM-CSF and IL-5 in the experimental group was much lower than that of the control group.@*CONCLUSION@#SIT decreases the expression of GM-CSF and IL-5 and reduces the inflammatory reaction in the tissue samples of recurrent nasal polyps.
Subject(s)
Humans , Enzyme-Linked Immunosorbent Assay , Granulocyte-Macrophage Colony-Stimulating Factor , Metabolism , Immunotherapy , Inflammation , Drug Therapy , Interleukin-5 , Metabolism , Nasal Mucosa , Pathology , Nasal Polyps , Drug Therapy , Metabolism , Rhinitis, Allergic, Perennial , Drug Therapy , MetabolismABSTRACT
OBJECTIVE@#To investigate specific immunologic therapy (SIT) intervention in patients with nasal polyps accompanied with perennial rhinitis after functional endoscopic sinus surgery (FESS).@*METHOD@#To divide patients with nasal polyps into two groups randomly: group I: FESS + SIT after operation; group II: FESS only. To compare the symptom and physical sign of the 2 groups before the operation and 1 and 2 years after the operation, with SNOT-20 and Lund-Kennedy and Lund-Mackay Standard.@*RESULT@#Both of the 2 groups' final scores of the total 20 items and the most important 5 items of SNOT-20 and Lund-Kennedy and Lund-Mackay were greatly improved, however there is an obvious difference between them: the therapeutic effect of groups I is better than group II.@*CONCLUSION@#SIT can reduce the recurrence of nasal polyps after operation, and improve the state after treatment.